CD19 Fc Chimera Protein, Human

1μg (R: reducing conditions, N: non-reducing conditions)

The purity of CD19 Fc Chimera Protein, Human is more than 95% determined by SEC-HPLC.

2e5 of transient transfected anti-CD19 ScFv CAR-293 cells were stained with 0.01ug  CD19 Fc Chimera Protein, Human, (Cat. No. UA010042)  and unlable respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa Fluor 647 signal was used to evaluate the binding activity. 2e5 of transient transfected anti- CD19 ScFv CAR-293 cells were stained with isotype and Whitlow/218 Linker-Alexa Fluor® 488 (Fig. D and E). Alexa Fluor® 488 signal was used to evaluate the binding activity.

Immobilized FMC63 at 1.0μg/mL (100μL/well) can bind CD19 Fc Chimera Protein, Human (Cat. No. UA010042 ) with EC50 of 2.89-4.07ng/mL, bind CD19 Fc Chimera Protein, Human (competitor) with EC50 of 7.77-10.10ng/mL.

Immobilized CD19 Fc Chimera Protein, Human (Cat. No. UA010042)at 2.0μg/mL (100μL/well) can bind Biotinylated Denintuzumab with EC50 of 2.86-3.66ng/mL.